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Background:  The long-term outcomes of sirolimus-eluting stents (SES) compared with bare metal stents (BMS) in ST-segment elevation 
myocardial infarction (STEMI), especially in regard with hard end points, have not been well characterized.
Methods:  A meta-analysis of randomized controlled trials (RCT) for long-term follow-up, defined as equal to or more than 2 years, was performed 
to evaluate the benefits and safety of SES as compared to BMS in patients undergoing primary angioplasty for STEMI. The databases searched for 
RCT included PubMed, Embase, Cochrane Library, Web of Science, and the U.S. National Institute of Health.
Results:  A total of 4 trials were included in this meta-analysis, involving 1,304 patients (656 patients were randomized to SES and 648 patients 
were randomized to BMS). At 2 to 4 years, SES showed a significant reduction in mortality (Figure) as well as target lesion revascularization (odds 
ratio: 0.41, 95% confidence interval: 0.28-0.59, p<0.00001) compared with BMS. On the other hand, the ratios of recurrent myocardial infarction 
and stent thrombosis were comparable between the 2 groups.
Conclusions:  In this meta-analysis, primary angioplasty for STEMI patients with SES was associated with more favorable long-term outcomes 
compared to those with BMS. 
